![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin: Data From the ELECTRON Trials
|
|
|
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), March 12Ð15, 2014, Brisbane, Australia
Edward J. Gane,1 Robert H. Hyland,2 Xiao Ding,2 Evguenia S. Svarovskaia,2 Phillip S. Pang,2
William T. Symonds,2 John G. McHutchison,2 Catherine A. Stedman3
1Auckland Clinical Studies, Auckland, New Zealand; 2Gilead Sciences, Inc., Foster City, CA, USA; 3Christchurch Clinical Studies Trust, Christchurch, New Zealand
![APASL1.gif](../images/031714/031714-6/APASL1.gif)
![APASL2.gif](../images/031714/031714-6/APASL2.gif)
![APASL3.gif](../images/031714/031714-6/APASL3.gif)
![APASL4.gif](../images/031714/031714-6/APASL4.gif)
![APASL5.gif](../images/031714/031714-6/APASL5.gif)
![APASL6.gif](../images/031714/031714-6/APASL6.gif)
![APASL7.gif](../images/031714/031714-6/APASL7.gif)
![APASL8.gif](../images/031714/031714-6/APASL8.gif)
![APASL9.gif](../images/031714/031714-6/APASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|